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Abstract
Intercellular signaling by cytokines is a vital feature of the innate immune system. In skin, an inflammatory response is 
mediated by cytokines and an entwined network of cellular communication between T-cells and epidermal 
keratinocytes. Dysregulated cytokine production, orchestrated by activated T-cells homing to the skin, is believed to be 
the main cause of psoriasis, a common inflammatory skin disorder. Cytokines are heavily regulated at the 
transcriptional level, but emerging evidence suggests that regulatory mechanisms that operate after transcription play 
a key role in balancing the production of cytokines. Herein, we review the nature of cytokine signaling in psoriasis with 
particular emphasis on regulation by mRNA destabilizing elements and the potential targeting of cytokine-encoding 
mRNAs by miRNAs. The proposed linkage between mRNA decay mediated by AU-rich elements and miRNA 
association is described and discussed as a possible general feature of cytokine regulation in skin. Moreover, we 
describe the latest attempts to therapeutically target cytokines at the RNA level in psoriasis by exploiting the cellular 
RNA interference machinery. The applicability of cytokine-encoding mRNAs as future clinical drug targets is evaluated, 
and advances and obstacles related to topical administration of RNA-based drugs targeting the cytokine circuit in 
psoriasis are described.
Introduction
Cytokines are intercellular signaling proteins that serve as
key modulators of the immune system and inflammation.
Cells respond to extracellular stress or stimuli by operat-
ing intracellular signaling cascades that coordinate cellu-
lar gene expression through complex networks of kinase
activation, protein phosphorylations, and activation of
DNA-binding proteins that translate signals at the cell
surface to actions of transcriptional regulation of cellular
genes. Cytokines modulate the communication between
cells of the immune system and between immune cells
and differentiated somatic cells. Upon binding to their
cognate receptor on the cell surface, cytokines trigger
transcriptional changes and balance cellular activities
ranging from growth to differentiation and cell survival.
Cytokine-directed transcriptional induction of yet other
cytokines may further enhance the innate immune
response in an increasingly entangled network of signals.
Genome-wide association studies have shown that
mutations of genes encoding cytokines, cytokine recep-
tors, or downstream players in the cellular signaling cas-
cades associated with autoimmune disease. Effectors of
the different signaling cascades and the transcriptional
regulation operated through these pathways have been
reviewed at numerous occasions. In this review, we con-
centrate exclusively on the posttranscriptional mecha-
nisms that act together to balance the expression of
cytokines during inflammation. The discovery of RNA
interference and the regulatory actions of small RNAs
have unveiled a new world of posttranscriptional regula-
tion and yet new layers of complexity in cellular signaling
pathways that are in play during inflammation. Small
non-coding RNA species, produced from intronic and
intergenic regions across the mammalian genome, are
key players in post-transcriptional regulatory pathways of
gene expression. MicroRNAs (miRNAs) interact with
mRNAs and trigger translational suppression or mRNA
degradation through recruitment of cellular proteins.
Short-lived RNA transcripts, such as several cytokine-
encoding mRNAs, contain RNA destabilizing elements
and regulatory miRNA binding motifs that may in con-
cert contribute to stringent regulation of cytokine pro-
duction. Dysregulated cytokine production is a hallmark
of tissues affected by chronic inflammatory disease, and
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characterized, roles in aberrant cytokine regulation and
disease development and progression. With emphasis on
skin inflammation and psoriasis vulgaris in particular
(referred to as psoriasis in the remainder of the review),
we focus here on the regulation of cytokines at the RNA
level in relation to development of inflammatory disease.
We provide an overview of the network of cytokine sig-
naling in psoriasis and its regulation through induced
RNA destabilization and miRNA association and the
potential linkage between mRNA decay and targeting by
miRNA. The applicability of cytokine-encoding mRNAs
as future therapeutic targets is evaluated, and obstacles
and advances related to topical administration of RNA-
based drugs targeting the cytokine circuit in psoriasis are
described.
Psoriasis is an idiopathic chronic skin disorder which
has been estimated to affect about 2% of the population
world-wide [1-3]. The disease manifests in different clini-
cal variants, the most predominant form being plaque
psoriasis affecting about 80% of all psoriasis patients.
Plaque psoriasis shows as erythematous and scaly lesions
that are red or salmon pink in color and often covered by
white or silvery scaly plaques [4]. Adding to the physical
distress, severe psychosocial aspects of psoriasis can
strongly impact the quality of life [5,6]. Histologically,
psoriasis displays a thickened epidermis (epidermal
hyperplasia), dilated and prominent blood vessels in the
dermis caused to some extent by an up-regulation of vas-
cular endothelial growth factor (VEGF), and an inflam-
matory infiltrate of leukocytes predominantly in the
dermis.
The epidermal hyperplasia is associated with underex-
pression of keratinocyte differentiation markers, which
causes incomplete differentiation of keratinocytes (parak-
eratosis). Histopathologically this shows as retention of
nuclei of cells in the stratum corneum (the outer stratified
cell layer) and an overall thickening of the epidermis
(acanthosis). The transit time of keratinocytes from the
basal cell layer of the epidermis to the stratum corneum is
reduced from 28 days to about 4-7 days in psoriatic
lesions.
Many advances have been made in recent years in
unraveling the molecular mechanisms of psoriasis, but
many questions still remain unanswered. It is still not
known if the primary nature of the condition is epithelial
or immunologic and the autoimmune cause of the
inflammation is still to be uncovered [7]. Moreover, addi-
tional information regarding the relevance of cutaneous
versus systemic factors and genetic versus environmental
influences on disease initiation is still lacking. However, it
is widely accepted that a dysregulation of the immune
system by an alteration in the cytokine production pro-
vides persistent proinflammatory signals in the skin that
lead to psoriatic lesions. This is also supported by the fact
that psoriasis may be cured by allogenic bone marrow
transplantation [8] and that psoriasis may be transferred
from the bone marrow transplant donor to the recipient
[9]. Although a model involving dysregulated cytokines is
conceptually useful and therapeutically relevant, it does
not entail the full complexity of the disease or the more
than 1,300 genes that are differentially expressed in psori-
atic lesions [10].
Cytokine networks in psoriasis
Psoriasis is the result of an intensifying cross-talk
between skin-infiltrating immunocytes and epidermal
keratinocytes. An overview of the cell types and primary
cytokines involved in this intercellular communication is
provided in Figure 1. The leukocyte infiltrate in psoriatic
lesions consists primarily of dendritic cells, macrophages,
cytotoxic T cells and activated T-helper cells (Th cells).
Naïve CD4+ T-cells that are activated through interaction
with antigen-presenting cells (APCs) - primarily den-
dritic cells and macrophages - play a dominant role in
both initiation and persistence of the disease. Depending
on the exposure to different cytokines, naïve T-cells may
develop into one of the at least five different CD4+ T-cell
lineages that have been identified to date. Th1 cells play a
key role in clearance of intracellular pathogens, whereas
Th2 cells trigger and organize a defense response against
extracellular pathogens. The Th17 and Th22 lineages, the
latter which was just recently discovered [11], assist the
Th1 and Th2 lineages in inducing an inflammatory
response, whereas Treg cells serve to limit the immune
response by production of immunosuppressive cytokines
[12].
According to the classical Th1/Th2 model by which
naïve Th cells differentiate into either Th1 or Th2 cells
producing the defining cytokines interferon gamma
(IFNγ) and interleukin (IL)-4, respectively, psoriasis was
classified as a Th1 disease with a marked type 1 cytokine
profile [13]. This model was supported by the fact that a
shift in the cytokine production from a Th1 to Th2
cytokine profile was found to ameliorate the disease [14].
However, with the discovery of a new subset of Th cells,
Th17 cells [15], which seem to play a prominent role in
psoriasis [13], a new paradigm has taking over with psori-
asis being classified as a Th1/Th17 disease. Th17 cells are
named according to their production of IL-17, which in
turn induces the production of other proinflammatory
cytokines, such as TNFα, IL-6, IL-8 and IL-22 (Figure 1)
[16]. Identification of the Th22 lineage, which is charac-
terized by secretion of IL-22 and TNFα, but does not
express IFNγ, IL-4, or IL-17 [11], has caused yet another
paradigm shift [17]. Th22 cells represent a stable and
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that differs from those of Th1, Th2, and Th17 cells in
inflamed skin. Cells of the Th22 lineage appear to be
induced by Langerhans cells and dermal dendritic cells
[18], home preferentially to the epidermis, and are
thought to amplify proinflammatory signals induced by
TNFα in keratinocytes. Interestingly, there seems to be
some plasticity within the population of psoriatic skin-
homing Th cells. Hence, in addition to distinct popula-
tions of T-cells producing IFNγ (Th1), IL-4 (Th2), IL17
(Th17), and IL-22 (Th22), respectively, subsets of Th cells
expressing two or even three of these cytokines can be
identified [11]. It has been suggested, therefore, that sub-
sets of CD4+ Th cells may not necessarily represent dis-
tinct lineages but possibly Th cells at different levels of
differentiation [19], adding perhaps yet another layer of
complexity to the Th-directed orchestration of the innate
immune response in psoriatic skin.
Sabat and co-workers proposed a model for the patho-
genesis of psoriasis consisting of three phases [20]. The
sensitization phase includes antigen processing and pre-
sentation by primarily dendritic cells and macrophages
followed by generation and mobilization of activated T-
cells. A silent intervening phase is followed by the effec-
tor phase in which CD4+ and CD8+ T-cells and other
immune cells migrate to the skin and here undergo fur-
ther activation and proliferation. Keratinocytes are
involved in the cytokine-mediated inflammation by
responding to and producing cytokines. Cytokine-stimu-
lated keratinocytes are activated, and this process leads to
epidermal remodeling with increased proliferation and
dysregulated differentiation of keratinocytes. The kerati-
nocyte-produced cytokines (a subset is listed in Figure 1)
Figure 1 Schematic representation of the cytokine network driving development of psoriasis. Cytokines mediate intercellular communication 
between skin-infiltrating activated immune cells and epidermal keratinocytes. Resident T-cells and antigen-presenting cells are activated upon stim-
ulation by stress or infection (indicated by lightning symbol), leading to production of cytokines, as indicated by horizontal arrow labeled with boxed 
cytokines. Naïve CD4+ T-cells undergo differentiation upon exposure to different cytokine milieus, as indicated by the listed cytokines driving the dif-
ferentiation into one of five T-helper (Th) cell lineages, Th1, Th2, Th17, Th22, or Treg. A subset of cytokines (listing is not intended to be absolute), pro-
duced by each of the Th lineages and macrophages, orchestrates a multi-faceted stimulation of epidermal keratinocytes. This leads to production of 
an additional set of cytokines triggering epidermal remodeling through altered keratinocyte growth and differentiation as well as angiogenesis. Num-
bers in blue ovals above cytokine names indicate the number of AUUUA pentamer sequences (potential ARE sequences) that are located in the 3'UTR 
of each cytokine mRNA (or for heterodimeric cytokines the number of AUUUA sequences in mRNA species encoding each of the two subunits). Also 
shown is the development of pre-psoriatic, non-lesional skin (left insert) to a psoriatic plaque (right insert) driven by activated immune cells and cy-
tokine-activated keratinocytes. The lesional skin section shows thickened epidermis with elongated retes and an abnormal outer skin layer (stratum 
corneum) with formation of epidermal scales. Skin-infiltrating immune cells (including activated Th cells, dendritic cells, and macrophages) are visible 
in the dermis.
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cell trafficking, immune cell adhesion to endothelial cells
and promotion of angiogenesis [21]. Additionally, kerati-
nocytes produce antimicrobial peptides which have
chemotactic as well as immune cell modulating functions
[22]. These are just some of the functions of keratinocytes
in psoriasis pathogenesis which further complicate the
issue regarding the psoriatic dogma of epidermal kerati-
nocytes versus immune cells as being the main contribu-
tor to disease initiation and continuance.
Current therapeutic strategies targeting the cytokine 
network in psoriasis
Current therapies for psoriasis include topical agents,
phototherapy and systemic therapies. Topical therapies
are mainly used for mild psoriasis and in addition to the
widely used corticosteroids, keratolytic ointments, topi-
cal retinoids and vitamin D analogues are also used [23].
Phototherapy and systemic therapies are mostly used in
moderate to severe psoriasis. The systemic therapeutic
approach is mainly based on modulating either keratino-
cyte proliferation, T-cell activities or key players in the
cytokine network [24]. Common non-biological systemic
therapies include ciclosporin, methotrexate, oral retin-
oids and psoralen. Biological therapeutics, in contrast,
are relatively new in psoriasis treatment and are currently
based on recombinant receptors or antibodies targeting
either T-cell function or cytokines [25].
In an extremely complex network of cytokine-directed
intercellular signaling, different subsets of cytokines seem
crucial at different stages of the pathogenesis. TNFα play
a key role during naïve T-cell activation, whereas IFNγ,
IL-12, IL-4, IL-6, TGF-β, and IL-23 are prime mediators
of Th differentiation (Figure 1). Th-derived IFNγ, IL-6, IL-
17, IL-22, and TNFα as well as several cytokines derived
from dendritic cells and macrophages are prominent reg-
ulators of the keratinocyte response which will in turn
result in the production of a number of cytokines includ-
ing IL-6, IL-8, IL-20, and IL-23 (Figure 1). All cytokines in
the pathogenesis may in theory represent useful thera-
peutic targets. Inhibitors of TNFα as an absolute key
player have been applied to psoriasis in animal models
and/or patients with great success. Especially TNFα
inhibitors such as Infliximab, Etanercept, and Adal-
imunab have proven their worth in inflammatory condi-
tions such as rheumatoid arthritis, Crohn's disease and
ulcerative colitis [26]. More recently, systemic adminis-
tration of such inhibitors of TNFα has been established as
a potent treatment of severe psoriasis [27,28].
More recently, drugs simultaneously targeting IL-12
and IL-23 have been developed. Both IL-12 and IL-23 are
up-regulated in psoriatic lesional skin [29]. As heterodi-
meric cytokines, they share the subunit p40 encoded by
the IL-12B gene. Both interleukins are expressed by den-
dritic cells and macrophages, but also to some extent by
keratinocytes [30,31]. IL-12 is produced early after APC
activation and works in a paracrine fashion by stimulat-
ing natural killer cells to produce IFNγ and on naïve T-
cells to drive their differentiation into Th1 cells [32].
Thereby, IL-12 is considered an important factor in initi-
ating and driving the Th1 cytokine profile that is present
in psoriasis. IL-12 can also work in an autocrine fashion
in which APC function is enhanced and contributes to
IFNγ production [33]. IL-23, in contrast, does not appear
to have a direct effect on naïve T-cells. However, this
cytokine seems to have a crucial role in the survival and
proliferation of Th17 cells, thereby promoting IL-17 pro-
duction. In fact, a study shows that IL-17 and IFNγ dis-
play a marked synergism in the stimulation of IL-6 and
IL-8 production by human keratinocytes [34]. This sug-
gests that IL-12 and IL-23, via their function in Th1 and
Th17 cell development, synergistically amplify inflamma-
tion through stimulation of keratinocytes to augment
their secretion of proinflammatory cytokines. Interest-
ingly, genetic polymorphisms in IL-12B and one of the IL-
23 receptor subunits (IL-23R), have been linked to psoria-
sis [35] and many of the current therapies used in treating
psoriasis, such as narrow-band UVB therapy [36], Etaner-
cept (soluble TNFα receptor) [37] and Alefacept (an
antagonist of T cell activation) [38] all reduce levels of IL-
23. The shared p40 subunit of IL-12 and IL-23 was con-
firmed as a potent therapeutic target with the approval of
Ustekinumab, a subcutaneously injected monoclonal
antibody directed against p40. In fact, in a phase III trial,
Ustekinumab showed to be more effective and to require
fewer injections than the TNFα-inhibitor Etanercept [39].
In spite of the recent success of biological cytokine-tar-
geting drugs, there is still a continued need for psoriasis
treatments that are safe, effective and convenient.
Patients may respond differently to biological agents, and
relapses may occur in some patients. Furthermore, there
is an increased occurrence of opportunistic infections
associated with the general immunosuppressive action of
these highly potent cytokine inhibitors. Hence, more evi-
dence is needed concerning the long-term safety of such
biological agents. However, the encouraging clinical
experience with anti-cytokine treatment has prompted
the search for and development of inhibitors of other
psoriasis-related cytokines. As a recent example of this,
findings in a xenotransplantation mouse model suggest
that blockage of IL-20 signaling by systemic administra-
tion of anti-IL20 antibodies leads to resolution of psoria-
sis [40].
Regulation of the cytokine network at the RNA level
The regulation of cytokine production is the very founda-
tion of the innate immune response during stress, infec-
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by several sets of genes affected by cellular signaling path-
ways is conceived by a network of transcription factors,
co-regulators, and epigenetic moderators. Signaling
routes and transcriptional control have been covered in
numerous reviews (see for example enlightening reviews
in references [41-43], and it is beyond the scope of this
review to cover such regulation. Instead, we will focus
here on cutaneous posttranscriptional regulation of
cytokine genes and the potential targeting of cytokine-
encoding mRNAs as a new therapeutic approach.
Decay of cytokine-encoding mRNAs triggered by AU-rich 
element
Many cytokine mRNAs are expressed as short-lived tran-
scripts. This instability is often conferred by functional
AU-rich elements (AREs) which are adenosine- and uri-
dine-rich sequences in the 3' UTR of not only multiple
cytokines, but also of numerous other genes - as much as
5-8% of human genes [44]. Computational predictions
have suggested that approximately half of the human
cytokine genes are regulated by ARE-mediated decay
(AMD) [45]. The action of AREs may be considered a
mechanism that limits, or buffers, gene expression after
production of the mRNA as a response to cellular altera-
tions and extracellular signals. There is relatively little
sequence similarity among AREs, but they generally con-
tain AUUUA pentamers and/or U-rich sequences [46].
Even though AREs are primarily characterized by their
ability to promote rapid deadenylation of mRNA tran-
scripts, some ARE-containing mRNAs, such as TNFα, are
also translationally regulated [47]. The far majority of the
key cytokine players in the psoriasis pathogenesis contain
AUUUA-pentamers localized in the 3' UTR of the mRNA
transcript. An overview of the numbers of potential AREs
in cytokine mRNAs involved in the pathogenesis of psori-
asis is given in Figure 1; numbers range from a total of 12
AUUUA-pentamers in the 3'UTR of the shared p40 sub-
unit (IL-12B) of IL-12 and IL-23 to one element in IL-19
and TGF-β. Only one of the cytokine mRNAs included in
this analysis, encoding IL-21, does not contain the
AUUUA sequence. The composition of the 3'UTRs and
location of computer-predicted ARE sequences (AUUUA
pentamers) is schematically presented for a selected sub-
set of psoriasis-related cytokine mRNAs in Figure 2.
The instability of ARE-containing mRNAs is regulated
by ARE-binding proteins (AUBPs) that belong to different
protein families and among which some promote destabi-
lization whereas others stabilize mRNAs. These proteins
modulate different aspects of mRNA metabolism includ-
ing deadenylation, exosome binding, or decapping and do
not seem to execute the RNA degradation themselves.
Instead AUBPs may facilitate mRNA recognition by ribo-
nucleases, including 3'-5' exoribonucleases in the multi-
component exosome complex [48] or 5'-3'
exoribonucleases in a more vaguely described non-exo-
somal degradation pathway [49].
Tristetraprolin (TTP), a member of the TIS11 protein
family, is a prominent AUBP that induces mRNA destabi-
lization and has been found to associate with a panel of
RNA degradation enzymes. TTP binds the ARE motif
(with preference for an RNA segment with the sequence
UUAUUUAUU) by means of two tandemly repeated zinc
finger domains [50] and was found first to limit produc-
tion of TNFα in macrophages by inducing destabilization
of the mRNA [51]. TTP promotes deadenylation which is
required for TTP-directed posttranscriptional regulation
[52], and the protein is regulated by phosphorylation
through the p38 MAPK pathway (described later). It was
recently shown that TTP, among other AUBPs, acts to
deliver ARE-containing mRNAs to processing bodies
which are cytoplasmic assemblies of mRNAs and compo-
nents of the RNA decay and silencing machinery [53].
TNFα mRNA is the most studied target of TTP, but a
series of other cytokines, including IL-6, IL-10, IL-12, and
granulocyte-macrophage colony stimulating factor (GM-
CSF) are potential targets with a role in psoriasis patho-
genesis. This notion is supported by the wide occurrence
of AUUUA-pentamers in cytokine transcripts (Figure 1
and 2) but remains to be studied in further detail. In addi-
tion, ARE-containing targets of other TIS11 family mem-
bers, like BRF-1 [54], include TNFα, IL-3, and GM-CSF.
The importance of TTP in regulating cytokine levels is
also illustrated by TTP knock-out mice which develop a
complex inflammatory phenotype and display inflamma-
tory arthritis, dermatitis, conjunctivitis and myeloid
hyperplasia caused by increased cytokine levels, espe-
cially of TNFα [55].
Other AUBPs compete with TTP and BRF-1 for bind-
ing to ARE sequences. T-cell intracellular antigen-1
(TIA-1) acts to destabilize TNFα mRNA, whereas Hu
protein R (HuR) increases the half-life of ARE-containing
mRNAs [56]. Other AUBPs like AUF-1, KSRP, and NF90
also affect the stability of ARE containing mRNAs
through association with degradation enzymes or com-
ponents of the exosome [56-61].
Regulation of ARE-mediated mRNA decay by p38 MAPK 
signaling
The mitogen activated protein kinase (MAPK) signaling
cascades are major pathways linking extracellular signals
to the intracellular machinery to regulate a plethora of
cellular processes such as embryogenesis and cell death,
stress, differentiation, and proliferation [62]. The cas-
cades contain at least three protein kinases in series cul-
minating in the activation of a MAP kinase. MAP kinases
are evolutionary conserved proteins and can be divided
into three subfamilies: extracellular signal-regulated
kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38
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are activated in response to different stimuli.
The p38 MAPK pathway has long been known to be
implicated in the regulation of the biosynthesis of some
cytokines [64]. There are four different p38 splice vari-
ants (α, β, γ, and δ) with p38α being the best character-
ized and probably the most physiologically relevant in
coordination and regulation of cellular responsiveness to
stress [65]. p38 activation can occur by a variety of extra-
cellular stimuli, including proinflammatory cytokines
such as IL-1 and TNFα, growth factors, osmolarity
changes, UV light, and chemical agents that promote
stress responses [66].
Downstream targets of p38α are multiple and include
cytosolic proteins, transcription factors, and several
kinases that elongate the cascade [67], but one target has
been identified that seems to be of particular importance
in regards to the involvement of p38α in cytokine regula-
tion, namely the MAPK-activated protein kinase 2
(MK2). MK2 is activated upon phosphorylation by p38α
[68] and the first evidence of MK2 being a key enzyme in
stress signaling came with the discovery that MK2-defi-
cient mice exhibited increased resistance to lipopolysac-
charide (LPS)-induced endotoxic shock [69]. Endotoxic
shock is mediated by proinflammatory cytokines and
LPS-challenged MK2-deficient mice had more than 90%
reduced TNFα serum levels compared to wild type mice.
Furthermore, LPS-stimulated cultured spleen cells from
these knock-out mice showed a marked reduction in lev-
els of TNFα, IFNγ IL-1β, IL-6, and IL-10.
Since then, numerous studies have been made in eluci-
dating the mechanisms of MK2 involvement in cytokine
regulation upon stress stimulation [50,70,71]. p38α is
reported to be involved in transcriptional control of
cytokines through several mechanisms [72,73], but there
is not much evidence of MK2 being directly involved in
transcriptional control of cytokines. However, one study
shows that MK2 can inhibit heat shock transcription fac-
tor 1 (HSF1) by phosphorylation [74]. HSF1 normally
represses cytokine promoters [75], and this function is
relieved by MK2 activation, thus promoting transcription
of cytokine genes.
In contrast, there is much evidence showing that MK2
is involved in post-transcriptional regulation of cytokines
including TNFα. The MK2 involvement in ARE-medi-
ated post-transcriptional regulation occurs via TTP,
which is, under normal cellular conditions, unphospho-
rylated and promote rapid ARE-mediated mRNA decay
Figure 2 Overview of pentameric ARE motifs and potential miRNA target sequences in psoriasis-relevant cytokines. The pentameric se-
quence motif, AUUUA, has been shown to be a discriminating motif for AREs which generally consist of clustered and/or overlapping pentamer re-
peats. miR-16 and miR-369-3p target sequence motifs in the ARE of TNFα, which are also present in multiple psoriasis-relevant cytokines as indicated 
by green and red bars, respectively. Target sites are shown by blue and purple bars, respectively, for miRNAs that are predicted by the PicTar (pic-
tar.mdc-berlin.de) and TargetScan (targetscan.org) algorithms to target psoriasis-relevant cytokines.
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can be phosphorylated by MK2 at multiple sites [76,77].
Upon p38α activation by stress stimuli, the stress signal is
transmitted through a p38α-MK2-TTP phosphorylation
cascade (Figure 3, right). Phosphorylation of TTP allows
it to interact with 14-3-3 proteins, which are chaperones
that stabilize specific conformations of a variety of pro-
teins [78]. The interaction of TTP with 14-3-3 interferes
with TTP-mediated recruitment of the exosome and
thereby stabilizes ARE-containing mRNAs [79]. The
exact mechanism of this has not yet been elucidated.
While some studies indicate that TTP exerts its function
in cytoplasmic foci called stress granules that arise in
response to some types of cellular stress, other studies
show that TTP also exerts its destabilizing function in the
cytoplasm of non-stressed cells. The main question still
exists, if the RNA stabilizing effect of TTP:14-3-3 com-
plex formation is due to physical sequestering of TTP
from the RNA or if it is caused by a direct inhibition of
exosome recruitment.
Only a limited number of studies have made a direct
link between the p38 MAPK pathway and psoriasis
pathogenesis. One of the first studies addressing this
aspect reported that up-regulated integrins in the supra-
basal epidermal layer of psoriatic skin activate various
MAPK pathways which in turn lead to unscheduled pro-
duction of cytokines and growth factors [80]. The link
between up-regulated integrins and psoriasis pathogene-
sis had at that time point already been established and
used in a transgenic mouse model of psoriasis in which
suprabasal epidermal expression of integrin subunits α2,
α5, and β3 led to a psoriatic-like phenotype, including
sporadic epidermal hyper-proliferation and a lympho-
cytic infiltrate [81]. Furthermore, the kinase activity of
p38α has been shown to be elevated in psoriatic lesions
with a concomitant decrease to normal levels upon reso-
lution of the disease [82].
Later it was shown that also the levels of activated MK2
were increased in psoriatic lesional skin compared to
non-lesional skin as measured by the degree of phospho-
rylated MK2 [83]. Interestingly, the same study reported
that increased TNFα protein levels in lesional psoriatic
skin were associated with normal TNFα mRNA levels.
Down-regulating MK2 in stress-stimulated primary kera-
tinocytes by administering MK2-targeting siRNAs led to
significantly reduced levels of TNFα, IL-6 and IL-8 com-
pared to controls. This indicates that increased activation
of MK2 may be responsible for the elevated levels of
Figure 3 Overview of the p38-MK2-TTP pathway. Upon normal cellular conditions the p38 MAPK pathway is not activated, which leaves TTP able 
to bind the ARE in the 3'UTR of ARE-containing mRNAs and recruit mRNA decay enzymes. Upon a stress stimulus, the p38 MAPK pathway is activated, 
initiating a phosphorylation cascade which result in the phosphorylation of TTP and a consequent 14-3-3-mediated sequestration of TTP from the ARE.
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scriptional regulation and likely through reduction of
TTP association with ARE sequences present in these
cytokine-encoding mRNAs (TNFα, IL-6 and IL-8 harbor
9, 6, and 9 AUUUA-pentamers, respectively; see Figure
2). Such regulatory mechanisms may apply to the expres-
sion of a variety of psoriasis-related cytokines, as sug-
gested by the wealth of potential AREs found in cytokine-
encoding transcripts.
The implication of p38α in cytokine regulation has, for
more than a decade, been of great interest in regards to
development of anti-inflammatory therapeutics. In addi-
tion to psoriasis, p38α has been shown to be involved in
several other inflammatory condition such as rheumatoid
arthritis, Crohn's disease, and asthma [84]. Several small-
molecule inhibitors of p38 have been developed which
are fairly specific for p38α and p38β [85]. Several of these
compounds have proven efficacious in preclinical studies
and at least 22 of these have entered clinical studies, how-
ever with discouraging results [84]. Some trials were dis-
continued due to lack of in vivo inhibitory potency and
inefficient oral bio-availability, but most studies were ter-
minated due to toxicities and significant off-target effects
reflecting the multiplicity of pathways and feedback loops
in the p38α cascade. Some trials are still ongoing and
have completed phase I and II, but there is still quite a lot
of skepticism about the clinical value of p38 inhibitors.
The problems regarding p38 inhibition might be cir-
cumvented by the use of MK2 inhibitors that can dissect
the p38 downstream pathways and interfere only with the
inflammatory part without affecting additional cellular
functions. Small molecule inhibitors and a peptide inhibi-
tor of MK2 have already been developed showing in vitro
and in vivo preclinical efficacy in inhibiting MK2 involve-
ment in cytokine regulation [86-89]. This lends support
to the notion that MK2 inhibition could provide new ave-
nues for anti-inflammatory therapies.
Fine-tuning gene expression by small RNAs - possible roles 
of miRNAs in psoriasis
An extensive and important group of non-coding RNAs
(ncRNAs) appeared with the discovery of miRNAs. More
than 700 different miRNAs have been identified in
humans and the pathway by which miRNAs exert
sequence-specific gene silencing has been elucidated,
though numerous questions still remain unanswered. The
miRNA pathway was found to converge with the RNA
interference (RNAi) pathway [90] by which double-
stranded RNA with sequence homology to the mRNA of
a particular gene induce post-transcriptional silencing of
that gene (Figure 4). The RNAi pathway was first sug-
gested to play a crucial role in a very efficient antiviral
mechanism against double-stranded RNA viruses but
now, with the discovery of miRNAs, also represent a key
path for tuning endogenous gene expression by post-
transcriptional regulation.
miRNAs are transcribed mainly from non-coding
regions by RNA polymerase II as long primary poly- or
monocistronic transcripts called pri-miRNA that are 5'
capped and polyadenylated. They can be up to several
kilobases long and can contain several distinct miRNAs
in short imperfect hairpins. In animals, these transcripts
are processed in the nucleus by the endoribonuclease
Drosha and the dsRNA-binding protein DGCR8 (a.k.a.
Pasha) [91,92]. Drosha cleaves the pri-miRNA in double-
stranded stem-loop regions, eleven nucleotides from a
hairpin junction, leaving 70-nt hairpins with a 2-nt 3'
overhang. These shorter transcripts are called pre-miR-
NAs and are transported to the cytoplasm by the
RanGTP-dependent exportin-5 [93]. In the cytoplasm
they are recognized by another endoribonuclease called
Dicer which processes the pre-miRNAs by removing the
hairpin and trimming the ends, leaving a mature ~21-nt
double-stranded miRNA with a 2-nt 3' overhang [94].
The double-stranded miRNA is associated with a class
of effector proteins called Argonaute (AGO) proteins
[95]. Humans have four of these proteins, AGO1 through
4, of which only AGO2 has been shown to be involved in
RNAi and is the only one which exhibits endoribonu-
clease activity. A potential link between miRNA process-
ing and ARE-directed mRNA degradation is suggested by
a possible association of AGO with TTP. The strand with
the lower thermodynamic stability at its 5' end remains
bound by AGO2 whereas the other strand, termed the
passenger strand, is either cleaved by AGO2 or dispelled
and degraded in the cytoplasm [96]. The incorporated
guide strand and AGO2 associate with other protein fac-
tors to form a larger ribonucleic protein (RNP) called the
RNA-induced silencing complex (RISC). By means of
base-pairing, the guide strand facilitates association of
RISC with target mRNA and depending on the degree of
sequence similarity between the guide strand and the tar-
get mRNA, regulation of gene expression can occur in
different ways [97,98]. Perfect or near-perfect sequence
similarity promotes mRNA cleavage through the action
of AGO2. Less degree of sequence similarity promotes
either translational repression by as-yet unknown mecha-
nisms or triggers the transport of the target mRNA to
mRNA-processing bodies [99].
In vertebrates, miRNAs mainly target the 3' UTRs of
the mRNAs, and the biological basis for this seems to be
that active translation of the miRNA target site impairs
miRNA inhibitory function [100]. The mRNA recogni-
tion occurs predominantly by complete sequence com-
plementarity in 6 nucleotides in the miRNA 5' end
(position 2-7) called the 'seed' region, although additional
basepairing increases miRNA functionality [98,101-104].
There is rarely full complementarity between the miRNA
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miRNA-mediated RNAi happens mainly through transla-
tional repression rather than cleavage.
Computational predictions suggest that a single
miRNA can target more than 200 mRNAs and, vice versa,
that a single mRNA can be under the regulatory control
of multiple miRNAs [105]. The substantial involvement
of miRNAs in regulating gene expression and the impor-
tance of miRNA contribution to essential cellular pro-
cesses make it no surprise that miRNAs also play a pivotal
role in both adaptive and innate immunity, including dif-
ferentiation of various immune cell subsets and regula-
tion of their immunological functions [106]. The
importance of miRNAs in T cell development is illus-
trated by a study in which miRNA processing was abro-
gated in mice by a conditional knock-out of Dicer. These
mice displayed impaired T cell development and aberrant
Th-cell differentiation with a preference towards Th1
induction and a consequent polarized cytokine produc-
tion [107]. By computational analysis based on three pre-
dictive algorithms, Asirvatham and co-workers searched
for miRNA target sites among 613 genes involved in reg-
ulating immunity [45]. Interestingly, only 10 out of 34
cytokine-encoding genes included in the analysis were
predicted to harbor miRNA target sites, whereas mRNAs
encoding AUBPs, crucial effectors of AMD, are poten-
tially heavily targeted by a larger subset of miRNAs [45].
As described later, posttranscriptional regulation by
AUBPs and miRNAs may be tightly and directly linked in
regulatory pathways in which noncanonical miRNA
binding to the mRNA contribute to ARE-directed mRNA
degradation.
Figure 4 Overview of RNA interference pathways. The RNA interference pathway is active in endogenous regulation of gene expression, in which 
pri-miRNAs are transcribed from the genome and processed in several steps ultimately leading to a mature miRNA which is loaded into the effector 
protein complex called RISC from where the guide strand of the miRNA guides RISC to mRNAs by sequence-specific target recognition. Depending 
on the degree of sequence similarity, RISC facilitates either translational suppression or mRNA degradation. The pathway can be exploited for se-
quence-specific down-regulation of a gene, by transfection of synthetic siRNAs or intracellular expression of shRNAs which are both efficiently pro-
cessed by the RNAi machinery and enter the RNAi pathway.
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ing evidence suggest that miRNAs play a role in regulat-
ing the network of cytokine signaling. A wealth of studies
link miR-155 to numerous pathways in the immune sys-
tem, strongly implying that miR-155 is a central regulator
of immune function. miR-155-deficient dendritic cells
showed impaired ability to activate T-cells [108]. miR-155
has been shown to target suppressor of cytokine signaling
1 (SOCS-1) [109] which negatively regulates the antigen
presenting ability of dendritic cells [110]. Higher levels of
SOCS-1 in the absence of miR-155 could therefore
account for the impaired dendritic cell function. The
reverse situation, in which SOCS-1 levels are reduced due
to miR-155 up-regulation, could be responsible for
uncontrolled dendritic cell function and in fact, in mac-
rophages and dendritic cells, miR-155 has been shown to
be up-regulated in response to stress stimulation by LPS
[111-113] and several studies report miR-155 up-regula-
tion in patients with rheumatoid arthritis [114,115] - an
inflammatory disorder that has an aberrant immune
response profile similar to psoriasis.
In vivo inhibition of miR-155 by intravenously injected
antagomirs, based on locked nucleic acid (LNA), in LPS-
treated mice showed a consequent down-regulation of
granulocyte-macrophage colony stimulating factor (GM-
CSF) mRNA in splenocytes through a yet unknown
mechanism [116]. GM-CSF is involved in inflammation
and rheumatoid arthritis patients have elevated levels of
GM-CSF which correlate with disease severity [117].
Conventional rheumatoid arthritis therapies that antago-
nize GM-CSF may lead to an abnormally low neutrophil
blood count. Hence, the authors suggest that partial
antagonism of endogenous GM-CSF by miR-155 inhibi-
tion might prove to be a novel therapeutic for the treat-
ment of rheumatoid arthritis and other chronic
inflammatory diseases. It still remains unanswered if
miR-155 plays a role in psoriasis, but to judge from its
central role in general immune function and in rheuma-
toid arthritis, there is reason to believe that miR-155
might also be implicated in psoriasis.
Like miR-155, miR-146 (miR-146a and miR-146b) has
also been found to be up-regulated in dendritic cells in
response to LPS stimulation and it has been shown to tar-
get two regulators of TNFα signaling, namely IL-1 recep-
tor associated kinase (IRAK1) and TNF receptor-
associated factor 6 (TRAF6) [112]. Thus miR-146 seems
to be involved in negatively regulating immune-respon-
sive genes which are induced by IRAK1 and TRAF6. To
appreciate the implication of IRAK1 and TRAF6 in TNFα
regulation, a study showed that RNAi-mediated repres-
sion of IRAK1 and TRAF6 in human monocytes resulted
in a 85% reduction in TNFα levels [114]. In contrast to
miR-146, miR-125b was found down-regulated in mac-
rophages in response to LPS stimulation and it was
reported to directly target TNFα mRNA. Hence, down-
regulation of miR-125b in response to LPS might be
required for proper TNFα production [113].
Careful miRNA profiling of miRNAs in lesional psori-
atic skin has been carried out by Sonkoly and co-workers
[118]. Interestingly, they found that miR-146 was up-reg-
ulated in psoriasis skin, whereas miR-125b was down-
regulated [119]. These are possibly secondary effects of
the inflammatory signals in psoriatic lesional skin rather
than direct contributors to psoriasis pathogenesis. Up-
regulated miR-146 in psoriasis is likely to be a negative
feedback mechanism in inflammation since it plays an
immuno-suppressive role. miR-125b can also be defined
as immuno-suppressive since it targets TNFα, but down-
regulation of miR-125b in psoriasis is not a protective
response, like up-regulation of miR-146, but rather a per-
missive response. miR-146 and miR-125b also differed in
their spatial expression in the various cellular constitu-
ents of the skin. miR-125b was mainly expressed in struc-
tural cells like fibroblasts, keratinocytes and melanocytes,
whereas miR-146 was virtually absent from structural
cells, and was instead expressed preferentially by immune
cells. Based on their described mechanisms, neither miR-
146 nor miR-125b seems to represent therapeutic targets
in psoriasis, but supplementing their levels by adminis-
tration of artificial miRNAs could potentially provide a
therapeutic response.
The best described miRNA with connection to psoria-
sis pathogenesis is miR-203. miR-203 is a skin-specific
miRNA expressed predominantly by keratinocytes [119].
miR-203 was found to be up-regulated in psoriasis and
computational predictions suggested that miR-203 tar-
gets SOCS-3 via an evolutionarily conserved 10-nucle-
otide sequence that includes the entire seed region and
carries perfect complementarity with SOCS-3 mRNA
[119]. In fact, miR-203 and SOCS-3 showed complemen-
tary expression in psoriatic epidermis: miR-203 was up-
regulated and SOCS-3 down-regulated compared to nor-
mal skin. SOCS-3 negatively regulates the activation of
the transcription factor signal transducer and activator of
transcription 3 (STAT-3) [120], which is indeed overly
active in psoriasis and implicated in cytokine signaling
[121]. Thus, up-regulated miR-203 in psoriasis might
have important implications for psoriasis pathogenesis by
preventing the up-regulation and negative feedback
mechanism of SOCS-3 on cytokine signaling.
However, another study questioned the link between
miR-203 and SOCS-3. The authors showed that exoge-
nously expressed miR-203 in murine keratinocytes did
not lead to repression of SOCS-3 protein [122]. On the
contrary, SOCS-3 levels were slightly up-regulated. How-
ever, this study was done in murine keratinocytes and
under non-inflammatory conditions, and, thus, it is still
possible that miR-203 targets SOCS-3 in human kerati-
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This seems to be supported by unpublished observations
from a luciferase-based reporter assay that validated tar-
geting of the SOCS-3 sequence by miR-203 (described in
[123]). In addition to being regulated by miR-203, SOCS-
3 carries a destabilizing ARE in its 3' UTR. A study in
murine fibroblasts and macrophages showed that stress-
induced p38 MAPK activation led to elevated SOCS-3
protein levels. It was also shown that this elevation was
mediated by activation of the p38-MK2-TTP axis with a
consequent stabilization of SOCS-3 mRNA [124].
Maintaining the cytokine balance - are miRNAs regulators 
of ARE-mediated mRNA decay in skin?
Numerous miRNA target sites in cytokine mRNAs are
predicted by computational analyses. A small subset of
such target sites - predicted with stringent search criteria
by two separate algorithms - are listed in Figure 2. Never-
theless, only very few targets have been functionally veri-
fied, and further experimental scrutiny is needed to
clarify the direct role played by miRNAs during cytokine
expression. Pioneering studies, however, suggest that
miRNAs are also involved in ARE-mediated regulation of
mRNA stability and translation [125]. Such mechanisms
are not merely directed by miRNAs targeting ARE motifs
by means of the canonical RNAi pathway but may include
also miRNA-mediated translational activation and
miRNA-assisted TTP binding to its target RNA.
miR-369-3p was found by Vasudevan and co-workers
to mediate translational activation of TNFα during cell
cycle arrest [126]. The TNFα ARE contains two identical
7-nt seed matches to miR-396-3p (Figure 5). The authors
showed that miR-369-3p base-pairs with this region and
recruits AGO2 and fragile X mental retardation-related
protein 1 (FXR1), which are both needed for translational
activation. It is important to note that the translational
activation was not merely an alleviation of translational
repression which corresponds to the translational activity
of an ARE-mutated TNFα transcript. AGO2 is the nor-
mal effector protein in RISC mediating post-transcrip-
tional repression of gene expression, but its involvement
in translational activation actually corresponds to the ini-
tial discovery of AGO2 as a translational stimulatory pro-
tein [127]. FXR1 is described as a translational regulator
that associates with the 60S ribosomal subunit [128], and
FXR1-knockout mice have been shown to exhibit
cytokine deregulation [129].
Even though the complete mechanism is not fully
understood, the finding that two other miRNAs, let-7 and
an artificial miRNA, also mediated translational activa-
tion during cell cycle arrest suggests that translational
regulation by miRNAs oscillates between repression and
activation as a function of the cell cycle. More studies will
have to be conducted to confirm this, but the described
relation between miR-369-3p and TNFα lends support to
the notion that miR-369-3p might be involved in aberrant
TNFα production and possibly other ARE-containing
cytokines. Another study links miR-155 to up-regulated
levels of a TNFα 3'UTR-containing reporter [113]. The
authors suggest a possible mechanism to be enhanced
translation of the transcripts caused by miR-155-medi-
ated suppression of proteins that bind to the TNFα 3'-
UTR and repress translation. Whether miRNA-mediated
activation of translation is involved in increased TNFα
production during inflammation still remains to be
explored and it would be an interesting study to investi-
gate if aberrant levels of miR-369-3p are produced during
inflammation. Other psoriasis-related cytokines contain
the miR-369-3p target sequence (Figure 2), and it is
intriguing, therefore, to speculate that miR-369-3p plays a
role also in regulating other mRNAs containing the same
ARE sequence as TNFα.
Like miR-369-3p, miR-16 also bears a partial sequence
match with the TNFα ARE - an 8-bp non-seed match
(Figure 5). Several studies confirm that the rapid ARE-
mediated decay of TNFα mRNA is mediated by the p38α-
MK2-TTP axis (Figure 3) [79], but a recent study showed
that miR-16 was also involved in the process and it was
shown that TTP and miR-16 are co-dependent in this
process [130]. miR-16 inhibition by antagomirs or
siRNA-mediated targeting of pre-miR-16 led to a marked
increase in TNFα mRNA stability. Furthermore, TTP was
identified in RISC bound to the ARE, leading the authors
to hypothesize that when bound to the ARE, miR-16-con-
taining RISC assists TTP binding to the ARE which
serves to recruit proteins for deadenylation and/or exo-
somes for mRNA degradation. The authors also investi-
gated the effect on two AREs from other mRNAs and
found that miR-16 was only involved in the regulation of
one of them. The study demonstrates the involvement of
miR-16 in controlling ARE-mediated mRNA decay of
some ARE-containing mRNA species and suggests that
cooperation of miR-16 and TTP is essential in the recog-
nition of these AREs and in triggering mRNA degrada-
tion (Figure 5). The caveats of this study, however, is that
it was either performed in drosophila S2 cells or HeLa
cells and the effects were only shown on a β-globin
reporter gene fused to the AREs. It remains unseen
whether production of TNFα in antigen-presenting cells
and keratinocytes is influenced by miR-16 and whether
this regulatory pathway is affected during skin inflamma-
tion. Attempts to modulate miRNA function in keratino-
cytes in culture should assist in clarifying these issues and
development of specific tools for antagonizing miRNA
function in xeno-transplanted lesional skin may help
define the roles of miRNAs during processing of TNFα
and other cytokines. Likewise, it remains a matter of
speculation whether the ubiquitously expressed miR-16,
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miR-16 target motifs in multiple cytokines (Figure 2),
represents a universal regulator of ARE-directed cytokine
regulation.
Towards the development of small RNA drugs for treatment 
of inflammatory skin disease
Our knowledge of small RNA-directed gene regulation is
constantly growing, and it seems safe to assume that so
far we have only seen the very tip of the iceberg with
respect to the many potential roles played by small RNA
regulators, adding to the enormous complexity of the
innate immune system. Inevitably, our understanding of
such regulation gives rise to new ideas of exploiting
nature's own regulatory pathways in drug development
and treatment of inflammatory disease. As we have seen,
cytokines are prominent targets for treatment of inflam-
matory diseases, like rheumatoid arthritis and psoriasis,
by systemically administered inhibitors. Do RNA-based
drugs represent new means of regulating cytokine signal-
ing during skin inflammation?
In recent years, a plethora of therapeutic possibilities
involving the use of double-stranded RNA (dsRNA) as a
drug has appeared [131], and several phase I and phase II
clinical trials are ongoing (reviewed in [132]). Like pre-
miRNAs, exogenous double-stranded RNAs (dsRNAs)
are recognized and processed in the cytoplasm by Dicer
into ~21-nt double-stranded RNAs termed small inter-
fering RNAs (siRNAs) (Figure 4). Elbashir and co-work-
ers showed first that cellular introduction of a 21-nt
duplex RNA was sufficient to mediate sequence-specific
gene silencing [133]. This was an important discovery for
utilizing the RNAi pathway for sequence-specific gene
silencing in studies of gene function and for therapeutic
silencing of aberrant gene expression since longer dsR-
NAs often provoke a severe cytotoxic interferon response
[134].
Transfection of synthetic siRNAs has the advantage
that the siRNAs do not need to reach the cell nucleus, but
it also suffers from the disadvantage that repeated admin-
istration is necessary to obtain a persistent effect because
the siRNAs are degraded and diluted during cell growth.
Sustained production of siRNAs is obtained by integrat-
able or episomally stable vector systems that encode
short hairpin RNAs (shRNAs) [135,136]. Like pre-miR-
NAs, shRNAs are exported from the nucleus by exportin-
5 and processed into siRNAs by Dicer. Synthetic siRNAs
that are transfected into cells can be taken into the RNAi
pathway at this point where they are recognized by
AGO2 and loaded into RISC which will mediate gene-
specific silencing, occurring mainly by mRNA cleavage
due to perfect target sequence similarity. shRNA expres-
sion systems represent powerful tools for knocking-down
disease genes including gain-of-function single basepair
mutant disease alleles. However, care must be taken in
the design of these highly discriminating siRNAs and also
for the use of siRNAs in general, due to the obvious risk
of off-target effects mediated by target complementarity
Figure 5 TNFα regulation by miR-16 and miR-369-3p. Sequence alignment of part of the TNFα 3'UTR and miR-16 or miR-369-3p. The core, non-
seed, recognition sequence is shown in bold. (A) TTP is associated with RISC and in a mutually dependent mechanism, TTP and miR-16 promote TNFα 
mRNA decay through binding to the TNFα ARE. The core non-seed miR-16 recognition motif is shown in bold. (B) miR-369-3p promotes canonical 
translational suppression or mRNA degradation during normal cellular conditions, but upon cell cycle arrest, FXR1 is associated with RISC to increase 
translational activity. The core miR-369-3p seed match is shown in bold.
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target regulation by miRNAs [137].
The applicability of locally administered cytokine-
directed RNAi therapeutics in skin inflammation seems
to depend on at least two key issues. Firstly, cytokine
mRNA targets need to be identified and validated in
appropriate animal models. Although prime candidates,
like TNFα-, IL23-, and IL20-encoding mRNAs, are easily
suggested as targets for RNA-based intervention based
on their suitability as targets for systemic protein inhibi-
tors, formal evidence for their potential as therapeutic
targets during inflammation is required. Secondly, the
delivery of RNAi therapeutics to skin remains an extraor-
dinary challenge to any type of cutaneous RNA-directed
therapy. A recent review by Geusens provides an excel-
lent view over the possibilities and hopes of RNAi therapy
in skin [138]. Here, we will discuss the prospects and
major challenges related to cytokine-directed RNAi ther-
apy.
TNFα is produced by skin antigen-presenting cells and
by keratinocytes during psoriasis progression and stands
out as one of several central cytokines in the pathogenesis
of the disease. Recent work by Johansen and co-workers
somewhat surprisingly showed that increased levels of
TNFα protein in lesional psoriatic skin was not caused by
an increase in the levels of TNFα-encoding mRNA but
rather by increased translational activity triggered by
higher levels of activated MK2 [83]. This suggests that
TNFα mRNA would not be perfectly suited as a target for
RNAi. However, given the roles played by TNFα we
hypothesized in recent work that targeting of TNFα
mRNA by local RNAi in the skin would serve as a poten-
tial strategy towards treatment of psoriasis [139].
To test this therapeutic approach, we identified one
shRNA variant, among a panel of DNA-encoded TNFα-
targeting shRNAs, that consistently induced down-regu-
lated expression of TNFα in cultured cells. We and others
have shown that transgenic genetic cargo is efficiently
delivered to cells of both the epidermis and dermis by
intradermally injected lentiviral vectors [139-141]. VSV-
G-pseudotyped lentiviral vectors were employed, there-
fore, to deliver the shRNA expression cassette to lesional
psoriatic skin translanted onto SCID mice. By intrader-
mal injection of a single dose of lentiviral vectors encod-
ing TNFα-targeted shRNAs, we measured a reduction in
the levels of TNF-α mRNA in transplanted skin and
observed both clinical and histological improvements of
the psoriasis phenotype. The severity of the psoriasis
phenotype, as determined by evaluating the clinical
scores of transplanted lesional skin, was improved by the
treatment to an extent that was comparable to that
observed in mice receiving systemically administered
cyclosporin A five times weekly for the duration of the
experiment (3 weeks). In addition, anti-TNFα shRNA
treatment reduced the epidermal thickness in the skin
xenografts. These findings together suggest that TNFα
mRNA is in fact a valid target for therapeutic interven-
tion by small RNAs. The data reveal the potential of
RNAi therapeutics in treatment of inflammatory skin dis-
ease and perhaps most importantly create a new platform
for performing systematic screening and evaluation of
therapeutic mRNA targets among the many cytokine and
cytokine-regulating players involved in psoriasis patho-
genesis. Hence, by combining gene-specific targeting
with lentiviral delivery it should be possible to target any
predetermined gene in transplanted psoriasis skin and
evaluate potential phenotypic improvements. On a longer
term, such studies are likely to benefit also from the
development of vectors that allow simultaneous expres-
sion of different shRNAs allowing estimations of the pos-
sible beneficial outcome of combinatorial treatments
targeting several prime players in disease development.
Despite its efficiency, intradermal administration of
lentiviral vectors is currently more an experimental tool
than a therapeutic modality in relation to inflammatory
skin diseases. Safety considerations, production costs,
and the fact that intradermal injection can be applied to
only small areas of skin are among the weighty reasons
that such treatment is not currently relevant for psoriasis
patients. Ironically, the potency of injected lentiviral vec-
tors illustrates some of the major challenges of cutaneous
RNAi therapy, namely the delivery of RNA effectors and
the ability of these to cross the major barriers of the skin.
As an easily accessible organ, skin stands out an attrac-
tive target for RNAi-based therapeutics. However, the
skin possesses strong barrier properties that impede easy
penetration of topically administered drugs (thoroughly
reviewed in [142,143]) and remain a challenge for devel-
opment of efficaciously delivered RNA drugs. Human
skin is composed of a dermis and an epidermis. Cells in
the basal layer (stratum basale) of the epidermis at the
dermis-epidermis interface proliferate and start to differ-
entiate upon initializing their migration towards the sur-
face of the skin. During migration, the differentiating
keratinocytes constitute the stratum spinosum and stra-
tum granulosom. Terminal differentiation occurs at the
stratum granulosom, and the migrating keratinocytes are
transformed into flat anucleated dead cells, corneocytes,
which constitute the densely packed stratum corneum,
the outer protective layer of the skin. Cells in this layer
are stacked and glued together by lipids embedding the
corneocytes. Under normal circumstances, loss of cells
from the stratum corneum is balanced by cell prolifera-
tion in the basal layer of the epidermis. Underlying the
epidermis is the dermis which is penetrated by blood and
lymphatic vessels and also embeds the hair follicles and
sweat glands.
Bak and Mikkelsen Journal of Biomedical Science 2010, 17:53
http://www.jbiomedsci.com/content/17/1/53
Page 14 of 19The tightly packed stratum corneum and narrow inter-
cellular compartments of the skin are the main challenges
for drug delivery to skin. Evidently, intradermally injected
lentiviral vectors are capable of overcoming both barriers,
as cells of both dermis and epidermis are efficiently trans-
duced after a single injection [139]. Similarly, uptake of
both plasmid DNA [144,145] and in vitro synthesized siR-
NAs [146,147] by keratinocytes after intradermal injec-
tion has been reported and may certainly have some
clinical applications. Recent findings have documented
targeting of chimeric luciferase reporter RNA molecules
by synthetic siRNAs injected into the paws of mice
[146,148]. Such data led to the proposal of a clinical trial
using siRNAs directed against keratin genes in patients
with the rare dominant-negative keratin disorder pachy-
onychia congenita [149]. The safety and efficacy of a
siRNA-based therapeutic for the treatment of pachyony-
chia congenita was recently evaluated in the first-in-
human siRNA clinical trial of an inherited skin disorder
[150]. Intradermal injection of TD101, a siRNA that
potently targets keratin 6a N171K mutant mRNA, was
carried out in a single patient. Adverse effects were not
reported, and the RNAi therapy induced regression of the
plantar callus which is one of the disabling features of the
disease, demonstrating a potential of such treatment that
may warrant further clinical investigations.
Despite the promises of intradermally injected siRNA
therapeutics or shRNA-expressing viral vectors, a topical
RNAi therapy remains the most attractive modality for
treatment of inflammatory skin disease. However, a topi-
cally applied RNA drug is confronted by the skin barrier
and may for some applications depend on penetration-
enhancing technologies. Topical administration of RNAi
therapeutics is generally considered safe and holds some
promise at present as a clinically applicable treatment.
Routes of skin permeation go through hair follicles and
sweat gland pores or through the narrow intercellular
space of the stratum corneum and the remainder of the
epidermis. The transport of RNA drugs by these routes
may be enhanced by microporation techniques that share
the common objective of increasing the permeability of
the stratum corneum [151]. Such techniques include the
use of microneedles coupled to drug transportation
[152,153] or exposure of the skin to ultrasound inducing
structural changes in the stratum corneum [154]. Elec-
troporation may also disrupt the structure of skin but has
so far typically been combined with intradermal injection
[155,156].
Physical methods may be accompanied by chemical
approaches including the use of chemicals that disrupt
the structure of the stratum corneum or lipid-based sys-
tems that are able to penetrate, although often with low
efficiency, the outer layers of the skin [157]. GeneCream,
a lipid-/alcohol-based formulation developed by Kaspar
and colleagues (now at TransDerm Inc., California, USA)
stands out as a promising siRNA formulation. Takanashi
et al. recently reported efficient topical delivery of siR-
NAs in mouse skin using the GeneCream formulation for
delivery of siRNAs targeting osteopontin mRNA [158].
Osteopontin enhances the production of IFNγ and IL-12
in macrophages and has been classified, therefore, as a
Th1 cytokine with a possible function in the pathogenesis
of inflammatory diseases. In situ hybridization of siRNAs
delivered with the GeneCream formulation showed
detectable levels of siRNA in both epidermis and dermis
shortly after topical drug administration. In addition,
osteopontin-directed siRNAs reduced the levels of osteo-
pontin mRNA in the skin and suppressed the disease
symptoms in a mouse model of rheumatoid arthritis
[158]. In another ground-breaking report, Ritprajak and
co-workers delivered CD86-targeting siRNAs emulsified
in baby lotion to the skin of a mouse model for allergic
skin disease [159]. CD86 is expressed on the surface of
antigen-presenting dendritic cells and plays a crucial role
in the activation status of dentritic cells and the antigen-
specific T-cell response. Knockdown of the CD86 path-
way resulted in reduced homing of dentritic cells in the
skin and in the lymph nodes, and, as a result, local
inflammation was reduced, demonstrating the potential
of targeting cutaneous dendritic cells in the RNA-
directed treatment of inflammatory disease. Based on
these recent examples in mice, cream-emulsified siRNA
delivery seems to match the capacities of viral vectors,
even without physical penetration-enhancing methodol-
ogies, and certainly holds clinical promise as a noninva-
sive and patient-friendly treatment of psoriasis and other
inflammatory skin diseases. It will be important in the
near future to further investigate the permeation of
cream-emulsified siRNAs in human skin.
Conclusions
Another layer of complexity has been added to the circuit
of cytokine signaling with the discovery of ARE-mediated
mRNA decay and translational control by miRNAs inter-
acting with cytokine-encoding mRNAs. Computational
analyses prophesy numerous potential mRNA-miRNA
interactions, but only few have so far been confirmed by
experimentation, and we are only starting to appreciate
the RNA regulatory pathways that are in play during
inflammation and inflammatory disease. We do not yet
have a feeling with the proportions of the involvement of
miRNAs in ARE-mediated decay of cytokine mRNAs,
and the roles of miRNAs mediated by noncanonical bind-
ing to cytokine-encoding mRNAs have been impossible
to foresee by computer-based predictions. Microarray
data have clearly shown that certain miRNAs are up- or
down-regulated in psoriasis skin [119]. These findings
strongly indicate that miRNAs play a role in inflamma-
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been scratched with respect to potential roles of miR-203,
miR146, and miR-125b. Whether dysregulation of miR-
NAs during inflammation in skin is a result of unbal-
anced cytokine signaling or a causative reason for disease
development is currently unclear and need further exper-
imental scrutiny. In addition, it is not currently known
whether ARE-directed regulation of TNFα is triggered by
miRNAs in skin, as was shown for miR-16 and miR-369-
3p in human cell cultures, and whether such interactions
may apply to other cytokines and could be involved in the
pathogenesis of psoriasis.
Our understanding of the molecular mechanisms driv-
ing an escalated immune response in skin may give rise to
alternative therapeutic strategies for treatment of psoria-
sis. Current therapies for psoriasis include topical agents,
phototherapy and systemic therapies including non-bio-
logical drugs, like ciclosporin, or biological therapeutics,
like recombinant cytokine receptors or antibodies. Does
local targeting of cytokine-encoding mRNAs represent a
future possible treatment? We have shown that cytokine
mRNAs can indeed be targeted in psoriatic skin and that
such artificial regulation of gene expression may induce
amelioration of the disease in an animal model. This
effect was achieved by intradermal injection of viral vec-
tors encoding TNFα-directed shRNAs and demonstrated
that knockdown of a single cytokine gene - despite any
potential redundancy - may improve the phenotype. One
may speculate if such local treatment - as opposed to a
systemic approach - will persistently reduce the influx of
T cells in the skin. Indeed, skin-homing immune cells will
not be exposed to the drug before entering layers of the
skin. In any case, the establishment of such drug regimes
awaits the development of effective methods for topical
delivery of synthetic siRNAs. We have seen the first
examples of such formulations and are eager to learn
more about the delivery and applicability of cream-emul-
sified cytokine-directed siRNAs in human skin and for
treatment of psoriasis in the xenograft transplantation
model. This seems a very promising approach although it
may at present suffer from the high costs related to pro-
duction of siRNAs.
If the future tells us that miRNAs are major players in
inflammatory disorders, a new generation of RNA drugs
could include small antisense RNAs that antagonize
miRNA function. Such antagomirs can be synthetically
made [160] or encoded by DNA [161] and may specifi-
cally target an overexpressed disease miRNA. As an
example of such strategy, targeting of miR-122 in mouse
liver by synthetic stabilized RNA antagomirs has been
reported [160] and has recently been followed up by the
use of miR-10b-directed antagomirs in cancer treatment
including anti-metastatic therapy [162]. As our scrutiny
of the cytokine circuit driving skin inflammation is inten-
sified, new therapeutic targets will appear. Despite the
current limitations in understanding RNA-directed regu-
lation of cytokines and delivering RNA drugs to human
skin, further investigation into cytokine-directed RNA
therapy is justified by a vast therapeutic potential.
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